StocksMedium•20 November 2026•
4 min read

Scorpion Capital Announces Short Position in Abivax After 11-Month Investigation

By

Key Facts

1Scorpion Capital announced that it held a short position in Abivax and said its investigation lasted 11 months.
2Reuters said Abivax’s U.S.-listed shares fell about 47% from the start of 2026 through November 20.
3ABVX closed at about $80.65 on November 19, 2026, according to EL7 records.
4Abivax reported 402.4 million euros in cash and short-term investments on June 30, and net offering proceeds of 767.1 million euros, with a cash runway into the fourth quarter of 2029.

Scorpion Capital announced that it held a short position in Abivax and said it had conducted an 11-month investigation, Reuters reported on November 20, 2026. The announcement puts a report by a firm betting on the stock’s decline at the center of the development concerning the company, but the stock’s movement in that day’s session cannot be confirmed from the information available here. The information also does not establish that the report caused selling pressure or specify the scale of any daily move. Reuters reported allegations from Scorpion questioning the scientific basis of Abivax’s claims and the properties and safety of its drug obefazimod. These allegations remain attributed to the report and do not represent independently confirmed findings.

Among the report’s claims, Reuters said, was that laboratory tests conducted by Scorpion suggest obefazimod could be phototoxic and carcinogenic. The description refers to a specific allegation about the drug, but in this account it remains a claim attributed to the short seller. Abivax did not immediately respond to a Reuters request for comment on the report. The article therefore contains no immediate response from the company to Scorpion’s allegations. The central dispute concerns the company’s lead drug and the scientific basis for its claims about it.

Abivax says obefazimod, also known as ABX464, is in Phase 3 clinical trials to treat moderately to severely active ulcerative colitis. That places the drug at an advanced stage of clinical development, according to the company’s own description. The allegations concerning its properties and safety carry weight in light of the testing program Abivax has announced, without resolving the trials’ outcome. The source reporting Scorpion’s accusations attributes them to its report, while the company describes the drug as its lead drug candidate. The available facts offer no independent judgment that resolves the competing accounts of the short seller and the company.

The development comes against a backdrop of earlier weak stock performance: Reuters said Abivax’s U.S.-listed shares had fallen about 47% since the start of 2026 through November 20. That figure describes the decline since the start of the year and does not measure the stock’s movement in the session when Scorpion announced its position. It also does not by itself establish a link between the earlier performance and the report or quantify the announcement’s effect on trading. In EL7 data, ABVX closed at about $80.65 on November 19, 2026. That price is for the previous session and does not provide a confirmed closing price for November 20.

On the financial front, Abivax said cash and cash equivalents and short-term investments totaled 402.4 million euros on June 30, 2026. The company added that net proceeds from the public offering completed in early July amounted to 767.1 million euros. According to its September 21 announcement, those resources together provided a cash runway into the fourth quarter of 2029. These figures describe the funding the company announced to finance its operations, while Scorpion’s allegations focus on the drug’s scientific basis and safety. Abivax also said the buyback of royalty certificates was completed in the second quarter of 2026, and that the transaction reduced its royalty burden and strengthened its debt-free financial position.

The company’s upcoming dates include a presentation at the Deutsches Eigenkapitalforum on November 23, 2026, according to the events schedule published by Abivax. The company also listed its third-quarter results announcement for December 14, 2026. The two dates follow Scorpion’s announcement of its short position and report, at a time when Abivax had not immediately responded to Reuters’ request for comment. The forum presentation and quarterly results are the next two events on the company’s published schedule. The available information included no further details about the presentation’s content or expectations for the third-quarter results.

Sources

Open on chart